GSK/Ligand Promacta win FDA priority review in severe aplastic anemia
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline won a priority review from the FDA for Promacta (eltrombopag) as a treatment for cytopenias in patients with severe aplastic anemia (SAA) who have had insufficient response to immunosuppressive therapy (IST).